Logo

Siemens and Biomax Partner in Gene Expression Simulation

Aug 18, 2004

NEW YORK, Aug. 18 (GenomeWeb News) - German companies Siemens and Biomax Informatics announced today that they will collaborate in the area of gene expression modeling and simulation.

 

Under the terms of the agreement, Siemens will use its BioSim gene expression simulator to uncover specific interdependencies in gene expression data, while Biomax will use its BioXM gene expression tool to place the correlations "in a relevant functional and biological context," the companies said in an official statement.

 

Financial terms of the deal were not disclosed.

Breaking News
The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.